Nektar Therapeutics
NASDAQ:NKTR

  • LAST PRICE
    1.8300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.8000/ 12
  • Ask / Lots
    1.8600/ 1
  • Open / Previous Close
    0.0000 / 1.8300
  • Day Range
    ---
  • 52 Week Range
    0.4126
    1.9280
  • Volume
    5,052

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 9, 2024

      Show headlines and story abstract

    • 4:39PM ET on Thursday May 09, 2024 by MT Newswires
      Companies Mentioned: NKTR
      04:39 PM EDT, 05/09/2024 (MT Newswires) -- ...

    • 4:15PM ET on Thursday May 09, 2024 by PR Newswire
      Companies Mentioned: NKTR

      Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024.

      https://mma.prnewswire.com/media/1390052/nektar_logo.jpg

      Cash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026.

    • 4:15PM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: NKTR
      net 17,475 18,856 Operating lease right-of-use assets 17,267 18,007 Other assets 4,656 4,644 Total assets $ 396,012 $ 398,033 ======================== ======================== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable 8,757 9,848 Accrued expenses 24,281 22,162 Operating lease liabilities, current portion 19,368 19,259 ------------------------ ------------------------ Total current liabilities 52,406 51,269 Operating lease liabilities, less current portion 94,710 98,517 Liabilities related to the sales of future royalties, net 117,857 112,625 Other long-term liabilities 4,334 4,635 Total liabilities 269,307 267,046 ------------------------ ------------------------ Commitments and contingencies Stockholders' equity: Preferred stock - - Common stock 19 19 Capital in excess of par value 3,644,140 3,608,137 Treasury stock (3,000) - Accumulated other comprehensive income (loss) (403) 80 Accumulated deficit (3,514,051) (3,477,249) Total stockholders' equity 126,705 130,987 ------------------------ ------------------------ Total liabilities and stockholders' equity $ 396,012 $ 398,033 ======================== ======================== (1) The consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share information) (Unaudited) Three months ended March 31, --------------------------------------------------------- 2024 2023 --------------------------- ---------------------------- Revenue: Product sales $ 6,034 $ 4,718 Non-cash royalty revenue related to the sales of future royalties 15,508 16,861 License, collaboration and other revenue 97 15 Total revenue 21,639 21,594 --------------------------- ---------------------------- Operating costs and expenses: Cost of goods sold 8,534 7,060 Research and development 27,408 30,469 General and administrative 20,149 21,081 Restructuring, impairment and costs of terminated program 975 21,193 Impairment of goodwill - 76,501 Total operating costs and expenses 57,066 156,304 --------------------------- ---------------------------- Loss from operations (35,427) (134,710) --------------------------- ---------------------------- Non-operating income (expense): Non-cash interest expense on liabilities related to the sales of future royalties (5,531) (6,405) Interest income 4,220 4,335 Other income (expense), net (99) (301) Total non-operating income (expense), net (1,410) (2,371) --------------------------- ---------------------------- Loss before provision for income taxes (36,837) (137,081) Provision (benefit) for income taxes (35) (63) Net loss $ (36,802) $ (137,018) =========================== ============================ Basic and diluted net loss per share $ (0.19) $ (0.73) =========================== ============================ Weighted average shares outstanding used in computing basic and diluted net loss per share 194,746 188,875 =========================== ============================

    • 4:15PM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: NKTR
      net 17,475 18,856 Operating lease right-of-use assets 17,267 18,007 Other assets 4,656 4,644 Total assets $ 396,012 $ 398,033 ======================== ======================== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable 8,757 9,848 Accrued expenses 24,281 22,162 Operating lease liabilities, current portion 19,368 19,259 ------------------------ ------------------------ Total current liabilities 52,406 51,269 Operating lease liabilities, less current portion 94,710 98,517 Liabilities related to the sales of future royalties, net 117,857 112,625 Other long-term liabilities 4,334 4,635 Total liabilities 269,307 267,046 ------------------------ ------------------------ Commitments and contingencies Stockholders' equity: Preferred stock - - Common stock 19 19 Capital in excess of par value 3,644,140 3,608,137 Treasury stock (3,000) - Accumulated other comprehensive income (loss) (403) 80 Accumulated deficit (3,514,051) (3,477,249) Total stockholders' equity 126,705 130,987 ------------------------ ------------------------ Total liabilities and stockholders' equity $ 396,012 $ 398,033 ======================== ======================== (1) The consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share information) (Unaudited) Three months ended March 31, --------------------------------------------------------- 2024 2023 --------------------------- ---------------------------- Revenue: Product sales $ 6,034 $ 4,718 Non-cash royalty revenue related to the sales of future royalties 15,508 16,861 License, collaboration and other revenue 97 15 Total revenue 21,639 21,594 --------------------------- ---------------------------- Operating costs and expenses: Cost of goods sold 8,534 7,060 Research and development 27,408 30,469 General and administrative 20,149 21,081 Restructuring, impairment and costs of terminated program 975 21,193 Impairment of goodwill - 76,501 Total operating costs and expenses 57,066 156,304 --------------------------- ---------------------------- Loss from operations (35,427) (134,710) --------------------------- ---------------------------- Non-operating income (expense): Non-cash interest expense on liabilities related to the sales of future royalties (5,531) (6,405) Interest income 4,220 4,335 Other income (expense), net (99) (301) Total non-operating income (expense), net (1,410) (2,371) --------------------------- ---------------------------- Loss before provision for income taxes (36,837) (137,081) Provision (benefit) for income taxes (35) (63) Net loss $ (36,802) $ (137,018) =========================== ============================ Basic and diluted net loss per share $ (0.19) $ (0.73) =========================== ============================ Weighted average shares outstanding used in computing basic and diluted net loss per share 194,746 188,875 =========================== ============================

  • May 2, 2024

Peers Headlines